clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Petersen AM et al. [Resistance of Helicobacter pylori to clarithomycin]. 1998 Ugeskr. Laeg. pmid:9627511
Archimandritis A et al. Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori. 1998 J. Intern. Med. pmid:9627163
Roussel G and Igual J Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. 1998 Int. J. Tuberc. Lung Dis. pmid:9626603
Tsuneoka H et al. [Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy]. 1998 Kansenshogaku Zasshi pmid:9621560
Kruppa A et al. Immediate reaction to roxithromycin and prick test cross-sensitization to erythromycin and clarithromycin. 1998 Dermatology (Basel) pmid:9621142
Torresani C Clarithromycin: a new perspective in rosacea treatment. 1998 Int. J. Dermatol. pmid:9620480
Fischer BP et al. [Tsutsugamushi fever. Rare rickettsiosis after a stay in the Philippines]. 1998 Dtsch. Med. Wochenschr. pmid:9615696
Lilley LL and Guanci R A dangerous combination. 1998 Am J Nurs pmid:9612423
Ramon PM et al. [Uveitis, arthralgia and pseudo-jaundice in a HIV seronegative patient due to rifabutin]. 1998 Rev Mal Respir pmid:9608993
Gavura SR and Nusinowitz S Leukocytoclastic vasculitis associated with clarithromycin. 1998 Ann Pharmacother pmid:9606474
Moayyedi P et al. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. 1998 J. Gastroenterol. pmid:9605943
Doherty TM and Sher A IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. 1998 J. Immunol. pmid:9605144
Harris A Current regimens for treatment of Helicobacter pylori infection. 1998 Br. Med. Bull. pmid:9604443
Fujita K et al. [Neutrophil count and IL-8 level of nasal secretion of patients with chronic paranasal sinusitis and the effects of macrolide antibiotics]. 1998 Jpn J Antibiot pmid:9597505
Miyamoto N et al. [Test to set dosages for long-term administration of clarithromycin to treat chronic paranasal sinusitis]. 1998 Jpn J Antibiot pmid:9597498
Sasa K et al. [Antineoplastic therapeutic effect of clarithromycin in rats]. 1998 Jpn J Antibiot pmid:9597492
Yano S et al. [Significance of therapeutic efficacy of clarithromycin in a model for human lung cancer metastasis and a mouse tumor system]. 1998 Jpn J Antibiot pmid:9597491
Kokubo Y et al. [Effect of clarithromycin on experimental pulmonary metastasis]. 1998 Jpn J Antibiot pmid:9597488
Ueta K et al. [Evaluation of BRM (biological response modifier) action of clarithromycin (CAM)--effect on cytokine expression in a mouse lung cancer model]. 1998 Jpn J Antibiot pmid:9597487
Teramoto S et al. [Effect of clarithromycin administration on interferon-gamma and interleukin 12 mRNA expression in the tumor tissue of non-small-cell lung cancer]. 1998 Jpn J Antibiot pmid:9597486
Sakamoto M et al. [Efficacy of clarithromycin (CAM) in patients with inoperable non-small-cell lung cancer]. 1998 Jpn J Antibiot pmid:9597485
Ieshiro R et al. [Effect of clarithromycin in extending the life expectancy of patients with non-small-cell lung cancer--the second report]. 1998 Jpn J Antibiot pmid:9597484
Enomoto F et al. [Changes in adhesion molecule expressions in neutrophils caused by new macrolide administration]. 1998 Jpn J Antibiot pmid:9597482
Isono K et al. [Effects of macrolide antibiotics on neutrophil infiltration into the airway mucosa and ICAM-1 expression]. 1998 Jpn J Antibiot pmid:9597480
Salgado CG et al. [Study on the effects of macrolide antibiotics on the expression of B7-1, B7-2, and CD40 on epidermal Langerhans cells]. 1998 Jpn J Antibiot pmid:9597478
Iino Y et al. [Immunohistochemical study of the paranasal sinus mucosa of patients being treated with macrolide antibiotics--effects of antigen-presenting cells on the expression of a costimulator]. 1998 Jpn J Antibiot pmid:9597477
Konishi M et al. [Log-term administration of clarithromycin as a possible adjuvant therapy of HIV infections]. 1997 Jpn J Antibiot pmid:9597467
Yanagihara K et al. [Analysis of chronic respiratory tract infection by using an intubation model--evaluation based on fluctuations in cytokine content]. 1997 Jpn J Antibiot pmid:9597463
Mita Y et al. [Vitamin D3 induction of differentiation of HL-60 cells to monocyte- like cells and their aggregation--a dynamic culture method and clarithromycin]. 1997 Jpn J Antibiot pmid:9597462
Takeda H et al. [Macrolide antibiotic actions on bacteria and cultured airway cells]. 1997 Jpn J Antibiot pmid:9597448
Mikasa K et al. [Effect of clarithromycin on prolonging the life expectancy of patients with primary lung cancer]. 1997 Jpn J Antibiot pmid:9597439
Teramoto S et al. [Fluctuation in the cytokine m-RNA content in primary non-small cell lung cancer caused by clarithromycin (CAM) administration]. 1997 Jpn J Antibiot pmid:9597438
Sakamoto M et al. [Efficacy of clarithromycin on cancer cachexia in patients with primary non-small cell lung cancer]. 1997 Jpn J Antibiot pmid:9597437
Kokubo Y et al. [Effects of clarithromycin on experimental pulmonary metastasis]. 1997 Jpn J Antibiot pmid:9597436
Hamada K et al. [Evaluation of antineoplastic effect of CAM (clarithromycin) in a mouse model inoculated with lung cancer cells]. 1997 Jpn J Antibiot pmid:9597434
Sugihara J et al. [Efficacy of clarithromycin on chronic paranasal sinusitis--a comparison between children and adult]. 1997 Jpn J Antibiot pmid:9597431
Koster F Paradoxical local response to therapy for Mycobacterium avium complex infection in four patients with AIDS. 1998 Clin. Infect. Dis. pmid:9597260
van Aarem A et al. Recurrent therapy resistant mastoiditis by Mycobacterium cheilonae abscessus, a nontuberculous mycobacterium. 1998 Int. J. Pediatr. Otorhinolaryngol. pmid:9596371
Spangler SK et al. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. 1998 Antimicrob. Agents Chemother. pmid:9593160
Sörberg M et al. Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9593154
Carr RA et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. 1998 Antimicrob. Agents Chemother. pmid:9593146
Goldstein EJ et al. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. 1998 Antimicrob. Agents Chemother. pmid:9593139
Liu W et al. [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. 1996 Zhonghua Nei Ke Za Zhi pmid:9592304
Chen S et al. [Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection]. 1996 Zhonghua Nei Ke Za Zhi pmid:9592303
Sousa C et al. [Cholestatic hepatitis probably induced by clarithromycin]. 1997 Gastroenterol. Clin. Biol. pmid:9587506
Hasegawa M et al. [In vitro activities of faropenem against clarithromycin resistance Helicobacter pylori isolates]. 1998 Kansenshogaku Zasshi pmid:9585692
Sheu BS et al. One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy. 1998 J. Formos. Med. Assoc. pmid:9585678
Tatsis G et al. Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections. 1998 J. Antimicrob. Chemother. pmid:9579716
Felmingham D et al. Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. 1998 J. Antimicrob. Chemother. pmid:9578171
Schwartz H et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. 1998 Am. J. Gastroenterol. pmid:9576452
Lee KL et al. QT prolongation and Torsades de Pointes associated with clarithromycin. 1998 Am. J. Med. pmid:9576415
Malfertheiner P and Blum AL [Helicobacter pylori infection and ulcer]. 1998 Chirurg pmid:9576033
Griesgraber G et al. Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. 1998 J. Med. Chem. pmid:9572891
Elliott RL et al. Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. 1998 J. Med. Chem. pmid:9572890
Jarboe E et al. Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin. 1998 Diagn. Microbiol. Infect. Dis. pmid:9572027
Scott BB Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. 1998 Aliment. Pharmacol. Ther. pmid:9570263
O'Connor HJ et al. Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? 1998 Aliment. Pharmacol. Ther. pmid:9570262
Dal Bo' N et al. Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks? 1998 J. Gastroenterol. Hepatol. pmid:9570242
Sonnenberg A et al. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. 1998 Arch. Intern. Med. pmid:9570170
Hoppe JE and Bryskier A In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). 1998 Antimicrob. Agents Chemother. pmid:9559823
Cheng KL et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. 1998 Antimicrob. Agents Chemother. pmid:9559810
Scheen AJ [Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)]. 1998 Rev Med Liege pmid:9555183
Iwata M et al. [Three cases of Fitz-Hugh-Curtis syndrome detected in the early stage by abdominal ultrasonography]. 1998 Nippon Naika Gakkai Zasshi pmid:9549331
Carnicer J [Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?]. 1998 Gastroenterol Hepatol pmid:9549199
Comet R et al. [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. 1998 Gastroenterol Hepatol pmid:9549183
Lindsetmo RO et al. Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy. 1998 Scand. J. Gastroenterol. pmid:9548613
Suzuki J et al. Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. 1998 Helicobacter pmid:9546120
Treiber G et al. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. 1998 Helicobacter pmid:9546119
Oberg KC Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. 1998 Mar-Apr Pharmacotherapy pmid:9545160
Perng CL et al. One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. 1998 Dig. Dis. Sci. pmid:9539638
Gisbert JP et al. [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. 1998 Med Clin (Barc) pmid:9527978
Kashuba AD and Amsden GW Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1998 Antimicrob. Agents Chemother. pmid:9527816
Collins LA et al. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. 1998 Antimicrob. Agents Chemother. pmid:9527783
Berquist WE New, improved Helicobacter pylori eradication therapy in children. 1998 J. Pediatr. Gastroenterol. Nutr. pmid:9523877
Alegre Herrera S et al. [Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia]. 1998 An Med Interna pmid:9522506
Laine L and Fendrick AM Helicobacter pylori and peptic ulcer disease. Bridging the gap between knowledge and treatment. 1998 Postgrad Med pmid:9519040
Trivedi S et al. Clarithromycin and digoxin toxicity. 1998 Ann. Intern. Med. pmid:9518419
Fattorini L et al. Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. 1998 Antimicrob. Agents Chemother. pmid:9517960
Hafner R et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. 1998 Antimicrob. Agents Chemother. pmid:9517944
Trevisani L et al. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. 1998 Am. J. Gastroenterol. pmid:9517646
Adamek RJ et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. 1998 Am. J. Gastroenterol. pmid:9517645
Bardhan KD et al. Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. 1998 Am. J. Gastroenterol. pmid:9517644
Williamson R et al. New options in Helicobacter pylori eradication: efficacy, resistance and synergy. 1998 Scand. J. Gastroenterol. Suppl. pmid:9515751
Moayyedi P Amoxycillin dual therapy against Helicobacter pylori--the final nail in the coffin? 1997 Ital J Gastroenterol Hepatol pmid:9513823
Sato K et al. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. 1998 J. Antimicrob. Chemother. pmid:9511040
Carlson LD et al. Standardized BACTEC method to measure clarithromycin susceptibility of Mycobacterium genavense. 1998 J. Clin. Microbiol. pmid:9508306
Rosina P et al. Fixed drug eruption from clarithromycin. 1998 Contact Derm. pmid:9506224
Ziering W and McElvaine P Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. 1998 Jan-Feb Infection pmid:9505188
Hocqueloux L et al. Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients. 1998 Chest pmid:9498982
Dubois A et al. Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates. 1998 J. Gastroenterol. pmid:9497216
Kusuhara H et al. Evaluation of combined antibiotic-omeprazole therapies in Helicobacter pylori-infected Mongolian gerbils. 1998 J. Gastroenterol. pmid:9497215
Payen MC et al. [Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection]. 1997 Rev Mal Respir pmid:9496599
Pérez Mota A et al. Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. 1997 Rev Esp Enferm Dig pmid:9494375
Boixeda de Miquel D [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer]. 1997 Rev Esp Enferm Dig pmid:9494374
Kondoh K and Hashiba M [Inhibitory effect of macrolide antibiotics on biofilm formation by Pseudomonas aeruginosa]. 1998 Nippon Jibiinkoka Gakkai Kaiho pmid:9493436
Hermon-Taylor J et al. Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease. 1998 BMJ pmid:9492675
Igea JM and Lázaro M Hypersensitivity reaction to clarithromycin. 1998 Allergy pmid:9491242
Ridgway GL et al. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. 1997 J. Antimicrob. Chemother. pmid:9484871
Hotz J [Reflux disease of the gastrointestinal tract. Acute therapy and long-term care in daily practice. 2. Therapeutic procedure--diagnosis--therapy-diagram]. 1997 Fortschr. Med. pmid:9480263
Cammarota G et al. Regression of a primary gastric MALT lymphoma with extensive antrum lesions by Helicobacter pylori eradication. 1997 Ital J Gastroenterol Hepatol pmid:9476192